KALO yields 666666.67% · JNJ yields 2.13%● Live data
📍 KALO pulled ahead of the other in Year 1
Combined, KALO + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of KALO + JNJ for your $10,000?
Kallo Inc., together with its subsidiaries, focuses on developing medical information technology software. The company's products in development include Electronic Medical Records (EMR) Integration Engine, a software, which connects various other applications in or outside a hospital/clinic with the EMR system; Communicable and Infectious Disease Information Management System, an Internet-based solution for monitoring and managing communicable and infectious disease information; and Clinical-Care Globalization, a clinical-care globalization technology. Its products also include MC-Telehealth, a mobile clinic with telehealth system technology; Kallo Integrated Delivery System (KIDS), a technology and process framework that defines and describes the component parts of the various products and services; and KIDS Global Tele-Health Ecosystems, a Tele-health Program that encompasses various technologies and administrative processes needed to deliver virtual medical care, health promotion/prevention, and other patient education to KIDS patients. The company was formerly known as Diamond Technologies Inc. The company was incorporated in 2006 and is headquartered in Toronto, Canada.
Full KALO Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.